Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NASDAQ:BCTX NASDAQ:CRVO NASDAQ:KYNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$1.57-4.8%$2.19$1.33▼$21.00$7.09M-2.0990,614 shs52,188 shsBCTXBriacell Therap$2.77+1.1%$3.82$2.60▼$34.70$23.84M1.21329,551 shs192,374 shsCRVOCervoMed$2.45+0.4%$3.50$2.13▼$13.13$22.59M-0.68127,711 shs131,778 shsKYNBKyntra Bio$7.13+5.5%$7.01$4.85▼$12.60$27.36M1.018,440 shs461,343 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals+3.12%-6.78%-19.51%-57.47%-76.43%BCTXBriacell Therap-4.86%-15.95%-32.84%-35.07%-92.15%CRVOCervoMed+8.44%-21.79%-35.28%-42.59%-67.34%KYNBKyntra Bio+1.05%-0.73%-6.37%-3.01%+675,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$1.57-4.8%$2.19$1.33▼$21.00$7.09M-2.0990,614 shs52,188 shsBCTXBriacell Therap$2.77+1.1%$3.82$2.60▼$34.70$23.84M1.21329,551 shs192,374 shsCRVOCervoMed$2.45+0.4%$3.50$2.13▼$13.13$22.59M-0.68127,711 shs131,778 shsKYNBKyntra Bio$7.13+5.5%$7.01$4.85▼$12.60$27.36M1.018,440 shs461,343 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals+3.12%-6.78%-19.51%-57.47%-76.43%BCTXBriacell Therap-4.86%-15.95%-32.84%-35.07%-92.15%CRVOCervoMed+8.44%-21.79%-35.28%-42.59%-67.34%KYNBKyntra Bio+1.05%-0.73%-6.37%-3.01%+675,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 2.00Hold$31.001,874.52% UpsideBCTXBriacell Therap 1.00SellN/AN/ACRVOCervoMed 2.63Moderate Buy$22.60822.45% UpsideKYNBKyntra Bio 2.50Moderate Buy$30.00320.76% UpsideCurrent Analyst Ratings BreakdownLatest ACXP, KYNB, CRVO, and BCTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026KYNBKyntra Bio Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.005/18/2026CRVOCervoMed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$9.004/23/2026CRVOCervoMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/22/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.004/20/2026ACXPAcurx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BCTXBriacell Therap Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CRVOCervoMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.003/18/2026CRVOCervoMed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $11.003/18/2026CRVOCervoMed Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $21.003/16/2026CRVOCervoMed D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$2.07 per shareN/ABCTXBriacell TherapN/AN/AN/AN/A$2.69 per shareN/ACRVOCervoMed$4.01M5.66N/AN/A$1.97 per share1.24KYNBKyntra Bio$6.44M4.48N/AN/A($4.20) per share-1.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$7.97M-$4.05N/AN/AN/AN/A-153.92%-101.69%8/10/2026 (Estimated)BCTXBriacell Therap-$26.31M-$23.33N/AN/AN/AN/A-153.53%-129.26%N/ACRVOCervoMed-$26.97M-$3.28N/AN/AN/A-672.80%-136.08%-112.62%8/14/2026 (Estimated)KYNBKyntra Bio$183.45M$40.46N/AN/AN/A2,199.13%N/A-36.71%N/ALatest ACXP, KYNB, CRVO, and BCTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/9/2026Q3 2026BCTXBriacell TherapN/A-$0.99N/A-$0.99N/AN/A5/15/2026Q1 2026CRVOCervoMed-$0.90-$0.86+$0.04-$0.86$0.07 millionN/A5/12/2026Q1 2026ACXPAcurx Pharmaceuticals-$0.59-$0.62-$0.03-$0.62N/AN/A3/13/2026Q4 2025CRVOCervoMed-$0.79-$0.88-$0.09-$0.88$0.84 million$0.01 million3/12/2026Q4 2025ACXPAcurx Pharmaceuticals-$1.01-$0.31+$0.70-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/ABCTXBriacell TherapN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AKYNBKyntra BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A3.783.78BCTXBriacell TherapN/A7.0710.10CRVOCervoMedN/A3.363.36KYNBKyntra BioN/A3.613.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%BCTXBriacell Therap15.42%CRVOCervoMed25.15%KYNBKyntra Bio72.71%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals20.30%BCTXBriacell Therap0.74%CRVOCervoMed35.40%KYNBKyntra Bio4.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals34.30 million3.43 millionNo DataBCTXBriacell Therap88.70 million8.64 millionNo DataCRVOCervoMed49.26 million5.98 millionNot OptionableKYNBKyntra Bio5704.05 million3.88 millionN/AACXP, KYNB, CRVO, and BCTX HeadlinesRecent News About These CompaniesKyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk ...June 11 at 7:37 PM | finance.yahoo.comKyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic SyndromesJune 11 at 4:05 PM | globenewswire.comKyntra Bio (NASDAQ:KYNB) Trading Down 1.5% - Here's WhyJune 6, 2026 | americanbankingnews.comKyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call TranscriptMay 11, 2026 | seekingalpha.comKyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue EstimatesMay 11, 2026 | zacks.comKyntra Bio to Report First Quarter 2026 Financial ResultsMay 4, 2026 | globenewswire.comKyntra Bio (KYNB) Upgraded to Buy: Here's What You Should KnowApril 14, 2026 | zacks.comKyntra Bio to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comKyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call TranscriptMarch 16, 2026 | seekingalpha.comKyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 16, 2026 | globenewswire.comKyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseMarch 9, 2026 | zacks.comKyntra Bio to Report Fourth Quarter and Full Year 2025 Financial ResultsMarch 9, 2026 | globenewswire.comKyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026February 23, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACXP, KYNB, CRVO, and BCTX Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$1.57 -0.08 (-4.85%) Closing price 04:00 PM EasternExtended Trading$1.61 +0.04 (+2.55%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Briacell Therap NASDAQ:BCTX$2.77 +0.03 (+1.09%) Closing price 04:00 PM EasternExtended Trading$2.77 0.00 (0.00%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.CervoMed NASDAQ:CRVO$2.45 +0.01 (+0.41%) Closing price 04:00 PM EasternExtended Trading$2.47 +0.02 (+0.98%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Kyntra Bio NASDAQ:KYNB$7.13 +0.37 (+5.47%) Closing price 04:00 PM EasternExtended Trading$7.04 -0.09 (-1.26%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
